Yahoo Finance

Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...
Yahoo Finance

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...
Yahoo Finance

How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...
Seeking Alpha

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki ...